Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 73 times since 2011 (5.8 per year) source: EuropePMC
Chest, Volume 141, Issue 4, 29 5 2011, Pages 935-943 Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Mauritz GJ, Kind T, Marcus JT, Bogaard HJ, van de Veerdonk M, Postmus PE, Boonstra A, Westerhof N, Vonk-Noordegraaf A
Background: Until now, many investigators have focused on describing right ventricular (RV) dysfunction in groups of patients with pulmonary arterial hypertension (PAH), but very few have addressed the deterioration of RV function over time. The aim of this study was to investigate time courses of RV geometric changes during the progression of RV failure. Methods: Forty-two patients with PAH were selected who underwent right-sided heart catheterization and cardiac MRI at baseline and after 1-yea... Abstract
Cited 49 times since 2011 (3.9 per year) source: EuropePMC
The American journal of cardiology, Volume 108, Issue 11, 3 1 2011, Pages 1645-1650 Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Mauritz GJ, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, Eilers P, Bosboom J, Postmus PE, Westerhof N, Vonk-Noordegraaf A
Previous studies have shown the prognostic benefit of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) in pulmonary arterial hypertension (PAH) at time of diagnosis. However, there are only limited data on the clinical utility of serial measurements of the inactive peptide NT-pro-BNP in PAH. This study examined the value of serial NT-pro-BNP measurements in predicting prognosis PAH. We retrospectively analyzed all available NT-pro-BNP plasma samples in 198 patients who were diagnosed with W... Abstract
Cited 24 times since 2011 (1.9 per year) source: EuropePMC
American journal of respiratory and critical care medicine, Volume 184, Issue 8, 28 4 2011, Pages 948-956 DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, Thunnissen FE, Duin S, Kooi C, Ylstra B, Meijer CJ, Meijer GA, Grünberg K, Daniels JM, Postmus PE, Smit EF, Heideman DA
Rationale: Autofluorescence bronchoscopy (AFB) is a valid strategy for detecting premalignant endobronchial lesions. However, no biomarker can reliably predict lung cancer risk of subjects with AFB-visualized premalignant lesions. Objectives: The present study set out to identify AFB-visualized squamous metaplastic (SqM) lesions with malignant potential by DNA copy number profiling. Methods: Regular AFB examinations in 474 subjects at risk of lung cancer identified six subjects with SqM lesions... Abstract
Cited 13 times since 2011 (1 per year) source: EuropePMC
Journal of the American Academy of Dermatology, Volume 66, Issue 2, 26 4 2011, Pages 259.e1-9 Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus. Starink TM, Houweling AC, van Doorn MB, Leter EM, Jaspars EH, van Moorselaar RJ, Postmus PE, Johannesma PC, van Waesberghe JH, Ploeger MH, Kramer MT, Gille JJ, Waisfisz Q, Menko FH
Background: Previously, we proposed that familial multiple trichodiscomas (OMIM 190340) is distinct from Birt-Hogg-Dubé syndrome (BHD) (OMIM #135150). BHD is characterized by multiple fibrofolliculomas/trichodiscomas, lung cysts, pneumothorax, and renal cell cancer. Germline FLCN mutations can be detected in most but not all BHD families. Objective: We sought to evaluate familial multiple trichodiscomas at a clinical and genetic level. We now renamed this condition "familial multiple discoi... Abstract
Cited 73 times since 2011 (5.7 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 47, Issue 17, 23 4 2011, Pages 2603-2606 Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF
Background: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially impressive response to EGFR-TKIs, patients with an activating EGFR mutation invariably relapse. For these patients few treatment options are available after additional progression during or after chemotherapy. The aim of this study is to examine the effect of retreatment with an EGFR-TKI after a drug holiday. Patients an... Abstract
Cited 29 times since 2011 (2.3 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 22, Issue 9, 4 1 2011, Pages 1973-1980 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, Felip E, Panel members
The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC,... Abstract
Cited 4 times since 2011 (0.3 per year) source: EuropePMC
The European respiratory journal, Volume 37, Issue 4, 1 1 2011, Pages 960-962 Cardiac shunt in COPD as a cause of severe hypoxaemia: probably not so uncommon after all. Boerrigter BG, Boonstra A, Westerhof N, Postmus PE, Vonk-Noordegraaf A
Cited 48 times since 2010 (3.6 per year) source: EuropePMC
American journal of respiratory and critical care medicine, Volume 183, Issue 10, 3 1 2010, Pages 1411-1418 Diaphragm muscle fiber weakness in pulmonary hypertension. de Man FS, van Hees HW, Handoko ML, Niessen HW, Schalij I, Humbert M, Dorfmüller P, Mercier O, Bogaard HJ, Postmus PE, Westerhof N, Stienen GJ, van der Laarse WJ, Vonk-Noordegraaf A, Ottenheijm CA
Rationale: Recently it was suggested that patients with pulmonary hypertension (PH) suffer from inspiratory muscle dysfunction. However, the nature of inspiratory muscle weakness in PH remains unclear. Objectives: To assess whether alterations in contractile performance and in morphology of the diaphragm underlie inspiratory muscle weakness in PH. Methods: PH was induced in Wistar rats by a single injection of monocrotaline (60 mg/kg). Diaphragm (PH n = 8; controls n = 7) and extensor digitorum... Abstract
Cited 5 times since 2010 (0.4 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 72, Issue 3, 9 2 2010, Pages 316-321 Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens. van den Berg RM, Snijders PJ, Grünberg K, Kooi C, Spreeuwenberg MD, Meijer CJ, Postmus PE, Smit EF, Steenbergen RD
Methylation-mediated silencing of the tumour suppressor CADM1 has been functionally linked to lung cancer development. We aimed to determine whether CADM1 promoter methylation is a candidate early detection marker for lung cancer. To this end frozen tissue samples of 36 non-small cell lung cancers, 26 corresponding tumour distant normal tissue samples as well as 6 samples of normal lung from non-lung cancer patients were tested for DNA methylation at three different regions within the CADM1 prom... Abstract
Cited 22 times since 2010 (1.6 per year) source: EuropePMC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 51, Issue 11, 18 3 2010, Pages 1684-1690 Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, Lammertsma AA, Lubberink M
Unlabelled: Quantification of tumor perfusion using radioactive water (H(2)(15)O) and PET is a promising method for monitoring treatment with antiangiogenic agents. However, use of dynamic H(2)(15)O scans together with a fully 3-dimensional clinical PET/CT scanner needs to be validated. The purpose of the present study was to assess validity and reproducibility of dynamic H(2)(15)O PET/CT scans for measuring tumor perfusion and validate the quantitative accuracy of parametric perfusion images. M... Abstract
Cited 39 times since 2010 (2.9 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 97, Issue 6, 7 1 2010, Pages 473-478 Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Mauritz GJ, Marcus JT, Westerhof N, Postmus PE, Vonk-Noordegraaf A
Background: In pulmonary arterial hypertension (PAH) a prolonged time interval between pulmonary valve closure and tricuspid valve opening is found. This period is interpreted as prolonged right ventricular (RV) relaxation, and thus a reflection of diastolic dysfunction. This concept recently has been questioned, since it was shown that RV contraction continues after pulmonary valve closure causing a post-systolic contraction period. Objectives: To investigate in PAH whether the increased RV pos... Abstract
Cited 101 times since 2010 (7.4 per year) source: EuropePMC
The European respiratory journal, Volume 37, Issue 6, 30 5 2010, Pages 1386-1391 Iron deficiency is common in idiopathic pulmonary arterial hypertension. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A
The aims of this study were to assess the prevalence of iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) and investigate whether oral iron supplementation has effects in iron-deficient patients. Iron parameters were measure for all IPAH patients attending our centre (VU University Medical Center, Amsterdam, the Netherlands) between May 2009 and February 2010. Iron data were related to clinical parameters, including 6-min walking distance (6MWD), and haemodynamic parameters me... Abstract
Cited 10 times since 2010 (0.7 per year) source: EuropePMC
Cancer, Volume 117, Issue 3, 24 4 2010, Pages 597-605 Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer. Lind JS, Lagerwaard FJ, Smit EF, Postmus PE, Slotman BJ, Senan S
Background: The optimal treatment of the primary tumor in patients with brain metastases (BM) from newly diagnosed nonsmall cell lung cancer (NSCLC) remains unclear. The authors aimed to identify patient groups with synchronous BM for whom radical treatment of the primary site may be appropriate. Methods: The medical records of 167 patients treated at our center between November 2000 and June 2009 for newly diagnosed NSCLC and synchronous BM were reviewed. All patients underwent surgery/radiosur... Abstract
Cited 58 times since 2010 (4.3 per year) source: EuropePMC
Chest, Volume 139, Issue 5, 23 4 2010, Pages 1003-1009 Clinically significant change in stroke volume in pulmonary hypertension. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques KMJ, Bronzwaer JGF, Heymans MW, Boonstra A, Postmus PE, Westerhof N, Vonk Noordegraaf A
Background: Stroke volume is probably the best hemodynamic parameter because it reflects therapeutic changes and contains prognostic information in pulmonary hypertension (PH). Stroke volume directly reflects right ventricular function in response to its load, without the correction of compensatory increased heart rate as is the case for cardiac output. For this reason, stroke volume, which can be measured noninvasively, is an important hemodynamic parameter to monitor during treatment. However,... Abstract
Cited 23 times since 2010 (1.7 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 5, Issue 9, 1 1 2010, Pages 1477-1480 Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. Becker A, van Wijk A, Smit EF, Postmus PE
Introduction: Currently, the inhibitor of the epidermal growth factor receptor tyrosine kinase erlotinib is widely used for the treatment of non-small cell lung cancer. Patients with a mutation or deletion in the epidermal growth factor receptor gene will benefit most and are likely to receive the drug for long periods and willing to accept side effects if responding. Methods: Twenty-two cases with prolonged administration of erlotinib (at least 6 months) and side effects are reported. Three cas... Abstract
Cited 103 times since 2010 (7.5 per year) source: EuropePMC
European respiratory review : an official journal of the European Respiratory Society, Volume 19, Issue 117, 1 1 2010, Pages 197-203 The arterial load in pulmonary hypertension. Saouti N, Westerhof N, Postmus PE, Vonk-Noordegraaf A
The anatomical differences between the pulmonary and systemic arterial system are the main cause of the difference in distribution of compliance. In the pulmonary arterial system compliance is distributed over the entire arterial system, and stands at the basis of the constancy of the RC-time. This distribution depends on the number of peripheral vessels, which is ∼8-10 times more in the pulmonary system than the systemic tree. In the systemic arterial tree the compliance is mainly located in th... Abstract
Cited 6 times since 2010 (0.4 per year) source: EuropePMC
International journal of oncology, Volume 37, Issue 2, 1 1 2010, Pages 455-461 Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. Van den Berg RM, Brokx H, Vesin A, Field JK, Brambilla C, Meijer CJ, Sutedja GT, Heideman DA, Postmus PE, Smit EF, Snijders PJ
Lung cancer is the most important cause of cancer-related mortality. Resectability and eligibility for treatment with adjuvant chemotherapy is determined by staging according to the TNM classification. Other determinants of tumour behaviour that predict disease outcome, such as molecular markers, may improve decision-making. Activation of the gene encoding human telomerase reverse transcriptase (hTERT) is implicated in the pathogenesis of lung cancer, and consequently detection of hTERT mRNA mig... Abstract
Cited 2 times since 2010 (0.1 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 5, Issue 8, 1 1 2010, Pages 1240-1245 The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteers. Schook RM, Postmus BB, van den Berg RM, Sutedja TG, Man de FS, Smit EF, Postmus PE
Background and study aims: Screening programs for lung cancer may lead to a heightened awareness of the risks of smoking and enhance quitting. The aim of this study was to evaluate whether the participation on a chemoprevention study for premalignant lesions could influence smoking cessation. Methods: Two hundred one volunteers, current (n = 188) and former smokers (n = 13) with more than 20 pack years had been screened for the chemoprevention study. One hundred forty-six of the current smokers... Abstract
Cited 53 times since 2010 (3.8 per year) source: EuropePMC
European radiology, Volume 20, Issue 12, 13 2 2010, Pages 2890-2898 Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, Postmus PE, Smit EF
Objective: We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome. Methods: DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23... Abstract
Cited 70 times since 2010 (5.1 per year) source: EuropePMC
American journal of respiratory and critical care medicine, Volume 182, Issue 10, 9 2 2010, Pages 1315-1320 Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus PE, Vonk-Noordegraaf A
Rationale: Pulmonary hypertension (PH) is characterized by increased arterial load requiring more right ventricular (RV) hydraulic power to sustain adequate forward blood flow. Power can be separated into a mean and oscillatory part. The former is associated with mean and the latter with pulsatile blood flow and pressure. Because mean power provides for net blood flow, the ratio of oscillatory to total power (oscillatory power fraction) preferably should be small. It is unknown whether this is t... Abstract